| hydrochlorothiazide / Generic mfg. |
NCT00778713: Bioequivalence Study of Fosinopril Sodium / Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fed Conditions |
|
|
| Completed | N/A | 33 | US | Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets | Ranbaxy Laboratories Limited | Healthy | 03/03 | 04/03 | | |
NCT00777972: Bioequivalence Study of Fosinopril Sodium/ Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fasting Conditions |
|
|
| Completed | N/A | 34 | US | Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets | Ranbaxy Laboratories Limited | Healthy | 03/03 | 04/03 | | |
NCT00778726: Bioequivalence Study of Benazepril HCl / Hydrochlorothiazide 20 mg/ 25 mg Tablets Under Fasting Conditions |
|
|
| Completed | N/A | 42 | US | Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets | Ranbaxy Laboratories Limited | Healthy | 10/04 | 12/04 | | |
NCT00778674: Bioequivalence Study of Benazepril HCl / Hydrochlorothiazide 20 mg/ 25 mg Tablets Under Fed Conditions |
|
|
| Completed | N/A | 30 | US | Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets | Ranbaxy Laboratories Limited | Healthy | 10/04 | 12/04 | | |
NCT00872235: Bioequivalence Study of Quinapril Hydrochloride 20 mg and Hydrochlorothiazide 25 mg Tablets Under Fed Conditions |
|
|
| Completed | N/A | 40 | RoW | fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets | Ranbaxy Laboratories Limited | Healthy | 07/05 | 11/05 | | |
NCT02336607: The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients. |
|
|
| Completed | N/A | 529 | RoW | Felodipine tablet (Plendil) alone, Felodipine tablet (Plendil)+Hydrochlorothiazide, Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK), Felodipine tablets (Plendil)+Lisinopril (Zestril) | AstraZeneca | Hypertension | 06/06 | 08/06 | | |
NCT00776646: Bioequivalence Study of Hydrochlorothiazide 50mg Tablets Under Fasting Conditions |
|
|
| Completed | N/A | 36 | RoW | hydrochlorothiazide 50 mg tablet | Ranbaxy Laboratories Limited, IPCA Laboratories Ltd. | Healthy | 06/06 | 08/06 | | |
CoCa, NCT00608153: Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide |
|
|
| Completed | N/A | 1773 | Europe | | AstraZeneca | Essential Hypertension | | 09/07 | | |
NCT01712139: Crossover Bioequivalence Study of Irbesartan HCTZ 300/25 mg Tablets Under Fasted Conditions |
|
|
| Completed | N/A | 37 | US | Irbesartan and Hydrochlorothiazide, Avalide | Roxane Laboratories | Hypertension | 09/07 | 09/07 | | |
NCT01712126: Crossover Bioequivalence Study of Irbesartan Hydrochlorothiazide 300/25 mg Tablets Under Fed Conditions |
|
|
| Completed | N/A | 40 | US | Irbesartan and Hydrochlorothiazide, Avalide | Roxane Laboratories | Hypertension | 09/07 | 09/07 | | |
CandLE, NCT00607633: Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH |
|
|
| Completed | N/A | 686 | Europe | | AstraZeneca | Essential Hypertension, Left Ventricular Hypertrophy | | 10/07 | | |
NCT00872781: Bioequivalence Study of Quinapril Hydrochloride 20 mg and Hydrochlorothiazide 25 mg Tablets Under Fasting Conditions |
|
|
| Completed | N/A | 64 | RoW | fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg tablets | Ranbaxy Laboratories Limited | Healthy | 10/07 | 12/07 | | |
COMBAT, NCT00526279: COmpliance and Efficacy in Mono and Combination Tablet Study ATacand/Atacand Plus |
|
|
| Completed | N/A | 9000 | RoW | | AstraZeneca | Hypertension | 08/08 | 08/08 | | |
NCT00160160: Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II Diabetes |
|
|
| Completed | N/A | 440 | Canada, Europe | eprosartan/HCTZ | Solvay Pharmaceuticals | Hypertension, Type 2 Diabetes | | | | |
NCT00617877: Antihypertensive Response to Losartan and Genetic Polymorphisms |
|
|
| Completed | N/A | 800 | Europe | losartan potassium, Comparator: Hydrochlorothiazide | Merck Sharp & Dohme LLC | Hypertension | 06/09 | 06/09 | | |
NASAA, NCT00999752: Study to Determine the Effects of Nebivolol and Hydrochlorothiazide in African Americans With Hypertension |
|
|
| Completed | N/A | 40 | US | Nebivolol, Bystolic, Hydrochlorothiazide, HCTZ | InVasc Therapeutics, Inc. | Hypertension | 02/10 | 05/10 | | |
NCT01071681: Survey to Assess Why People Are Not Responding to Treatment in Hypertension |
|
|
| Completed | N/A | 1589 | Europe | Telmisartan (Kinzal/Pritor, BAY68-9291) | Bayer, International Clinical Trials Association | Arterial Hypertension | 09/10 | 09/10 | | |
NCT02016183: Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets Special Drug Use Surveillance: Long-term Use (12 Months) |
|
|
| Completed | N/A | 3222 | Japan | Candesartan cilexetil / hydrochlorothiazide, ECARD® Combination Tablets LD&HD | Takeda | Hypertension | 09/12 | 09/12 | | |
NCT03021265: To Evaluate Real-world Safety, Effectiveness and Appropriate Use of Micatrio® Combination Tablets Treatment in Patients With Hypertension |
|
|
| Completed | N/A | 676 | Japan | T80/A5/H12.5 FDC, MICATRIO | Boehringer Ingelheim | Hypertension | 04/19 | 04/19 | | |
NCT03261375: To Evaluate Safety and Efficacy of a Radiofrequency Renal Denervation System in Treatment of Essential Hypertension |
|
|
| Completed | N/A | 205 | RoW | Renal Artery Radiofrequency Ablation System (Generator and Catheter ), Antihypertensive Agents, Nifedipine and hydrochlorothiazide, Sham Procedure | Shanghai Golden Leaf MedTec Co. Ltd | Hypertension | 12/22 | 12/22 | | |
NCT05413057: An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS/AML or FMS/AML/HCTZ |
|
|
| Recruiting | N/A | 20000 | RoW | | Boryung Pharmaceutical Co., Ltd | Hypertension,Essential | 06/26 | 06/26 | | |
FASTR-EU, NCT06362668: EU Sites: Fluid Management of Acute Decompensated Heart Failure With Reprieve Decongestion Management System |
|
|
| Recruiting | N/A | 30 | Europe | Reprieve Decongestion Management System, Diuretic (furosemide, bumetanide, torsemide, hydrochlorothiazide, and/or acetazolamide) | Reprieve Cardiovascular, Inc | Acute Decompensated Heart Failure | 10/24 | 12/24 | | |
NCT03511118: Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants |
|
|
| Recruiting | N/A | 1600 | Canada, US | Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI | 09/24 | 09/24 | | |
